Shares of Diploma PLC (LON:DPLM - Get Free Report) passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 4,609.28 ($62.92) and traded as high as GBX 5,487.50 ($74.90). Diploma shares last traded at GBX 5,440 ($74.26), with a volume of 175,203 shares traded.
Wall Street Analysts Forecast Growth
DPLM has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. reissued a "neutral" rating and issued a GBX 4,440 price objective on shares of Diploma in a research note on Wednesday, August 6th. Jefferies Financial Group boosted their price target on Diploma from GBX 4,500 to GBX 5,200 and gave the company a "hold" rating in a research note on Thursday, September 11th. Shore Capital reissued a "hold" rating and set a GBX 5,100 target price on shares of Diploma in a research note on Thursday, July 17th. Finally, Berenberg Bank boosted their target price on Diploma from GBX 5,750 to GBX 6,350 and gave the company a "buy" rating in a research report on Wednesday, September 10th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average target price of GBX 5,238.
View Our Latest Report on DPLM
Diploma Stock Down 0.9%
The company has a market cap of £7.31 billion, a PE ratio of 4,385.43, a P/E/G ratio of 2.82 and a beta of 0.75. The stock has a 50-day moving average of GBX 5,311.93 and a 200-day moving average of GBX 4,637.93. The company has a quick ratio of 0.80, a current ratio of 2.17 and a debt-to-equity ratio of 62.17.
Diploma Company Profile
(
Get Free Report)
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Stories
Before you consider Diploma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.
While Diploma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.